Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program

The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All ( = 251), ( = 51), ( = 16), and ( = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 a...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2017-03, Vol.61 (3)
Main Authors: Pfaller, Michael A, Messer, Shawn A, Rhomberg, Paul R, Castanheira, Mariana
Format: Article
Language:English
Subjects:
Antifungal Agents
Antifungal Agents - pharmacokinetics
Antifungal Agents - pharmacology
Asia - epidemiology
Aspergillosis - drug therapy
Aspergillosis - epidemiology
Aspergillosis - microbiology
Aspergillus fumigatus
Aspergillus fumigatus - drug effects
Aspergillus fumigatus - growth & development
Candida
Candida - drug effects
Candida - growth & development
Candidiasis, Invasive - drug therapy
Candidiasis, Invasive - epidemiology
Candidiasis, Invasive - microbiology
Cryptococcosis - drug therapy
Cryptococcosis - epidemiology
Cryptococcosis - microbiology
Cryptococcus neoformans
Cryptococcus neoformans - drug effects
Cryptococcus neoformans - growth & development
Drug Resistance, Fungal
Echinocandins
Echinocandins - pharmacokinetics
Echinocandins - pharmacology
Epidemiological Monitoring
Epidemiology and Surveillance
Europe - epidemiology
Fluconazole - pharmacokinetics
Fluconazole - pharmacology
Half-Life
Humans
Itraconazole - pharmacokinetics
Itraconazole - pharmacology
Latin America - epidemiology
Lipopeptides - pharmacokinetics
Lipopeptides - pharmacology
Microbial Sensitivity Tests
North America - epidemiology
Triazoles - pharmacokinetics
Triazoles - pharmacology
Voriconazole - pharmacokinetics
Voriconazole - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All ( = 251), ( = 51), ( = 16), and ( = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five isolates ( = 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on and ( = 92) and ( = 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of isolates, 4.3% of isolates, and 2.0% of and isolates. The activity of CD101 against ( = 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against ( = 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.02045-16